Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status

Wolff, 2013, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update, J Clin Oncol, 31, 3997, 10.1200/JCO.2013.50.9984 Wolff, 2018, Human epidermal growth factor receptor 2 testing in breast cancer: American society of Clinical oncology/college of American pathologists clinical practice guideline focused update, J Clin Oncol, 36, 2105, 10.1200/JCO.2018.77.8738 Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Slamon, 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, 707, 10.1126/science.2470152 Allison, 2020, Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update, J Clin Oncol, 38, 1346, 10.1200/JCO.19.02309 Ruschoff, 2017, Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany, Mod Pathol, 30, 217, 10.1038/modpathol.2016.164 Lux, 2018, Therapy landscape in patients with metastatic HER2-positive breast cancer: data from the PRAEGNANT real-world breast cancer registry, Cancers (Basel), 11, 10.3390/cancers11010010 Nowakowska, 2018, Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies, Cancer Immunol Immunother, 67, 25, 10.1007/s00262-017-2055-2 Ahmed, 2015, Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma, J Clin Oncol, 33, 1688, 10.1200/JCO.2014.58.0225 Mittendorf, 2012, Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02, Cancer, 118, 2594, 10.1002/cncr.26574 Ogitani, 2016, Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity, Cancer Sci, 107, 1039, 10.1111/cas.12966 Iwata, 2018, Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: long-term results of a large phase 1 study with multiple expansion cohorts, J Clin Oncol, 36, 10.1200/JCO.2018.36.15_suppl.2501 Saura, 2020, Trastuzumab deruxtecan in previously treated HER2-positive breast cancer, N Engl J Med, 382, 610, 10.1056/NEJMoa1914510 Fasching, 2019, Translational highlights in breast cancer research and treatment: recent developments with clinical impact, Curr Opin Obstet Gynecol, 31, 67, 10.1097/GCO.0000000000000510 Taran, 2018, Update breast cancer 2018 (Part 1) - primary breast cancer and biomarkers, Geburtshilfe Frauenheilkd, 78, 237, 10.1055/s-0044-101613 Schneeweiss, 2018, Update breast cancer 2018 (Part 2) - advanced breast cancer, quality of life and prevention, Geburtshilfe Frauenheilkd, 78, 246, 10.1055/s-0044-101614 Wockel, 2018, Update breast cancer 2018 (Part 3) - genomics, individualized medicine and immune therapies - in the middle of a new era: prevention and treatment strategies for early breast cancer, Geburtshilfe Frauenheilkd, 78, 1110, 10.1055/a-0715-2821 Muller, 2018, Update breast cancer 2018 (Part 4) - genomics, individualized medicine and immune therapies - in the middle of a new era: treatment strategies for advanced breast cancer, Geburtshilfe Frauenheilkd, 78, 1119, 10.1055/a-0715-2899 Tovey, 2006, Low expression of HER2 protein in breast cancer is biologically significant, J Pathol, 210, 358, 10.1002/path.2057 Eggemann, 2015, Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer, Endocr Relat Cancer, 22, 725, 10.1530/ERC-15-0335 Schmidt, 2016, Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer, J Cancer Res Clin Oncol, 142, 1369, 10.1007/s00432-016-2146-z Fasching, 2015, Biomarkers in patients with metastatic breast cancer and the PRAEGNANT study network, Geburtshilfe Frauenheilkd, 75, 41, 10.1055/s-0034-1396215 Hartkopf, 2018, Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - data from the German PRAEGNANT breast cancer registry, Breast, 37, 42, 10.1016/j.breast.2017.10.002 Muller, 2018, Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry, Breast, 37, 154, 10.1016/j.breast.2017.08.008 Hein, 2016, Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients, Breast Cancer Res Treat, 158, 59, 10.1007/s10549-016-3850-8 Salmen, 2014, Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies, Breast Cancer Res Treat, 148, 143, 10.1007/s10549-014-3130-4 Tarantino, 2020, HER2-low breast cancer: pathological and clinical landscape, J Clin Oncol, 38, 1951, 10.1200/JCO.19.02488 Eiger, 2021, The exciting new field of HER2-low breast cancer treatment, Cancers (Basel), 13, 10.3390/cancers13051015 Ignatov, 2015, Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade, Breast Cancer Res Treat, 151, 357, 10.1007/s10549-015-3407-2 Rossi, 2012, Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer, Oncol, 17, 1418, 10.1634/theoncologist.2012-0194 Gomez, 2010, Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients, Hematol Oncol Stem Cell Ther, 3, 109, 10.1016/S1658-3876(10)50020-7 Iwata, 2018, Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: long-term results of a large phase 1 study with multiple expansion cohorts, J Clin Oncol, 36, 10.1200/JCO.2018.36.15_suppl.2501 Tamura, 2019, Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study, Lancet Oncol, 20, 816, 10.1016/S1470-2045(19)30097-X Takegawa, 2019, [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification, Int J Cancer, 145, 3414, 10.1002/ijc.32408